GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Short-Term Debt

Vectus Biosystems (ASX:VBS) Short-Term Debt : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Short-Term Debt?

Vectus Biosystems's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Vectus Biosystems's annual Short-Term Debt increased from Jun. 2021 (A$0.44 Mil) to Jun. 2022 (A$5.89 Mil) but then declined from Jun. 2022 (A$5.89 Mil) to Jun. 2023 (A$0.00 Mil).

Vectus Biosystems Short-Term Debt Historical Data

The historical data trend for Vectus Biosystems's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Short-Term Debt Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial - - 0.44 5.89 -

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.44 5.89 - - -

Vectus Biosystems Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vectus Biosystems Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Short-Term Debt provided by Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines